THERAPY DOSSIER · th-3c99ce5cbd91

RS-130830 (Ro-1130830, CTS-1027)

Drug · Broad-spectrum matrix metalloproteinase inhibitor (INHIBITOR)

Evidence & regulatory context

Mechanism: Broad-spectrum matrix metalloproteinase inhibitor (INHIBITOR)
Target: CHEMBL333; CHEMBL321; CHEMBL283
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL440498 ↗
ChEMBL max phase: 2 / 4 (development scale, not regulatory approval)
Synonyms: CTS-1027; RO-1130830; RS-130830
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01051921 ↗PHASE2completed

Pegylated Interferon Plus Ribavirin in Combination With CTS-1027 in HCV Null-Responders

Hepatitis C

Enrolment: 67 · Results not recorded

NCT01273064 ↗PHASE2terminated

Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders

Hepatitis C

Enrolment: 114 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25890041 ↗2015Reported benefit

The matrix metalloproteinase inhibitor RS-130830 attenuates brain injury in experimental pneumococcal meningitis.

RatOtherWistarn = n=40 RS-130830, n=42 vehicle controlintraperitoneal75 mg/kgstarted 3 h post infection

Model: Pneumococcal meningitis induced by intracisternal injection of live Streptococcus pneumoniae, with ceftriaxone started 18 h post infection

Cortical necrosis was significantly attenuated by RS-130830 while hippocampal apoptosis was unchanged. CSF IL-1beta and IL-10 at 18 h post infection were significantly lower, and weight loss and CSF leukocyte counts were significantly reduced in treated survivors.

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…